Merck's earnings call highlighted continued strong performance, particularly in KEYTRUDA, and positive guidance for 2021.  The announcement of a leadership transition does not appear to significantly alter the short-term outlook.  Management expressed confidence in the company's future trajectory, suggesting likely short-term stock stability.
[1]
